Linganisha mbinu
Pitia mbinu ulizochagua bega kwa bega; safu zinazotofautiana zinaangaziwa.
| Kigezo cha Ufanano cha Umumunyifu f1/f2× | Kipimo cha Upenyezaji wa Seli za Caco-2× | |
|---|---|---|
| Nyanja | Famakolojia | Famakolojia |
| Familia | Process / pipeline | Process / pipeline |
| Mwaka wa asili≠ | 1996 | 1989 |
| Mwanzilishi≠ | James Moore and Hector Flanner | Ingrid Hidalgo |
| Aina≠ | similarity testing | absorption screening |
| Chanzo asilia≠ | Moore, J. W., & Flanner, H. H. (1996). Mathematical comparison of dissolution profiles. Pharmaceutical Technology, 20(6), 64-74. link ↗ | Hidalgo, I. J., Raub, T. J., & Borchardt, R. T. (1989). Characterization of the human colon carcinoma cell line (Caco-2) as a model system for intestinal epithelial permeability. Gastroenterology, 96(3), 736-749. DOI ↗ |
| Majina mbadala | f1, f2, similarity factor | Caco-2 assay, intestinal permeability, ADME screening |
| Zinazohusiana | 3 | 3 |
| Muhtasari≠ | The f1 and f2 factors are dimensionless statistical measures developed by Moore and Flanner to quantify the similarity between two dissolution profiles. Adopted by regulatory agencies (FDA, EMA) as the gold standard for comparing dissolution curves, these factors enable rapid assessment of whether formulation changes significantly impact drug release. | The Caco-2 assay is an in vitro model system using human colon carcinoma cell monolayers to screen drug intestinal permeability. Developed by Hidalgo and colleagues in 1989, Caco-2 cells differentiate into an epithelial barrier resembling intestinal mucosa, enabling rapid assessment of drug absorption potential and identification of transporter-mediated transport. |
| ScholarGateSeti ya data ↗ |
|
|